Physician profile
Suzanne G Spadafora
NPI 1912907650
$2,150.35
in general payments reported to CMS, 2019-2025
20 companies · $708 in 2025
The $708 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.66 · 2021: $180 · 2022: $433 · 2023: $473 · 2024: $342 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.91 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $237.46 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $233.97 | 2022-2025 | Ebglyss |
| Pfizer INC. | $200.89 | 2022-2025 | |
| Organon LLC | $159.47 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $154.93 | 2023-2025 | |
| Leo Pharma INC. | $144.33 | 2023-2025 | Adbry |
| Blueprint Medicines Corporation | $142.26 | 2024 | Ayvakit |
| Arcutis Biotherapeutics, INC. | $136.42 | 2023-2025 | Zoryve |
| Incyte Corporation | $124.99 | 2023 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $114.17 | 2023 | Sotyktu |
| Abbvie INC. | $98.88 | 2021-2025 | |
| Ucb, INC. | $80.45 | 2022-2025 | Bimzelx |
| Genzyme Corporation | $74.35 | 2023-2025 | |
| Galderma Laboratories, L.P. | $62.07 | 2025 | Nemluvio |
| Amgen INC. | $49.74 | 2023-2025 | Otezla, Enbrel, Otezla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $47.96 | 2021-2022 | |
| Dermavant Sciences, INC. | $23.97 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.02 | 2023 | Spevigo |
| Almirall LLC | $21.79 | 2021 | |
| Sun Pharmaceutical Industries INC. | $19.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Spadafora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.